SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 42 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $363,000 | +63.5% | 39,754 | -0.0% | 0.00% | – |
| Q4 2018 | $222,000 | -77.0% | 39,770 | -51.0% | 0.00% | – |
| Q3 2018 | $966,000 | +48.2% | 81,160 | +27.1% | 0.00% | – |
| Q2 2018 | $652,000 | +28.3% | 63,861 | +63.1% | 0.00% | – |
| Q1 2018 | $508,000 | +71.6% | 39,157 | +28.5% | 0.00% | – |
| Q4 2017 | $296,000 | -37.2% | 30,470 | -4.8% | 0.00% | – |
| Q3 2017 | $471,000 | -14.8% | 31,994 | -7.0% | 0.00% | – |
| Q2 2017 | $553,000 | +657.5% | 34,390 | +646.3% | 0.00% | – |
| Q1 2017 | $73,000 | +30.4% | 4,608 | 0.0% | 0.00% | – |
| Q4 2016 | $56,000 | – | 4,608 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,439,895 | $18,747,000 | 4.66% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $31,528,000 | 2.07% |
| Omega Fund Management, LLC | 2,274,831 | $12,398,000 | 1.40% |
| Altium Capital Management LP | 1,076,942 | $5,869,000 | 1.36% |
| Samsara BioCapital, LLC | 2,189,199 | $10,599,000 | 1.31% |
| Sio Capital Management, LLC | 800,000 | $4,360,000 | 1.08% |
| Flagship Pioneering Inc. | 2,938,494 | $16,015,000 | 0.20% |
| EcoR1 Capital, LLC | 1,000,000 | $5,450,000 | 0.20% |
| Artal Group S.A. | 1,700,000 | $9,265,000 | 0.19% |
| ACT CAPITAL MANAGEMENT, LLC | 52,500 | $287,000 | 0.15% |